Optimale Lysestrategien bei akutem Herzinfarkt: Trotzdem perkutane Koronarintervention (PCI)?

Die Senkung der kardiovaskulären Mortalität in den letzten Jahrzehnten ist unter anderem auf eine Senkung der Infarktmortalität zurückzuführen [6]. Diese war bedingt durch die Einführung der intensivmedizinischen Therapie, aber vor allem auch der kausalen Infarkttherapie durch die frühzeitige Thrombolyse und die interventionellen Therapieverfahren.

Literatur

• 1 Andersen H R, Nielsen T T, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen J K, Grande P, Villadsen A B, Krusell L R, Haghfelt T, Lomholt P, Husted S E, Vigholt E, Kjaergard H K, Mortensen L S. A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocardial Infarction.  N Engl J Med. 2003;  349 733-742
• 2 Becker R C, Burns M, Gore J M. et al . Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice: The National Registry of Myocardial Infarction (NRMI-2) Participants.  Am Heart J. 1998;  135 786-796
• 3 Bode C, Smalling R W, Berg G. et al . Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.  Circulation. 1996;  94 891-898
• 4 Cannon C P, Gibson C M, McCabe C H. et al . TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.  Circulation. 1998;  98 2805-2814
• 5 Fibrinolytic Therapy Trialists = (FTT) Collaborative Group . Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.  Lancet. 1994;  343 311-322
• 6 Goldberg R J, Samad N A, Yarzebski J, Gurwitz J, Bigelow C, Gore J M. Temporal trends in cardiogenic shock complicating acute myocardial infarction.  N Engl J Med. 1999;  340 1162-1168
• 7 The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.  N Engl J Med. 1993;  329 673-682
• 8 The GUSTO V Investigators . Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.  Lancet. 2001;  357 1905-1914
• 9 Hathaway W R, Peterson E D, Wagner G S. et al. GUSTO- Investigators . Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction.  JAMA. 1998;  279 387-391
• 10 Hochman J S, Sleeper L A, Webb J G. et al . Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.  N Engl J Med. 1999;  341 625-34
• 11 Johanson P, Jernberg T, Gunnarsson G, Lindahl B, Wallentin L, Dellborg M. Prognostic value of ST-segment resolution - when and what to measure.  Eur Heart J. 2003;  24 337-345
• 12 Juliard J M, Himbert D, Cristofini P. et al . A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty.  m J Cardiol. 1999;  83 305-310
• 13 Kovack P J, Rasak M A, Bates E R, Ohman E M, Stomel R J. Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock.  J Am Coll Cardiol. 1997;  29 1454-1458
• 14 Le May M R, Labinaz M, Davies R F. et al . Stenting versus thrombolysis in acute myocardial infarction trial (STAT).  J Am Coll Cardiol. 2001;  37 985-991
• 15 Magid D J, Calonge B N, Rumsfeld J S. et al, for the National Registry of Myocardial Infarction 2 and 3 investigators . Relation between the hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs. thrombolytic therapy.  JAMA. 2000;  284 3131-3138
• 16 Montalescot G, Barragan P, Wittenberg O. et al for the ADMIRAL Investigators . Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.  N Engl J Med. 2001;  344 1895-1903
• 17 Ross A M, Coyne K S, Moreyra E. et al . Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial.  Circulation. 1998;  97 1549-1556
• 18 Ross A M, Coyne K S, Reiner J S. et al . A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction. The PACT Trial.  J Am Coll Cardiol. 1999;  34 1954-1962
• 19 Ryan T J, Anderson J L, Antmann E M. et al . 1999 Update: American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the mangement of patients with acute myocardial infarction: executive summary and recommendations.  Circulation. 1999;  100 1016-1030
• 20 Sanborn T A, Sleeper L A, Bates E R. et al . Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry.  J Am Coll Cardiol. 2000;  36 1123-1129 (Suppl A)
• 21 Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, Winter H, Nickening G, Böhm M. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction.  J Am Coll Cardiol. 2003;  42 634-641
• 22 Schömig A, Ndrepepa G, Mehilli J, Schwaiger M, Schühlen H, Nekolla S, Pache J, Martinoff S, Bollwein H, Kastrati A. Therapy-Dependent Influence of Time-to-Treatment Interval on Myocardial Salvage in Patients With Acute Myocardial Infarction Treated With Coronary Artery Stenting or Thrombolysis.  Circulation. 2003;  108 1084-1088
• 23 Group (Strategies for the Patency Enhancement in the Emergency Department) . The SPEED Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction.  Circulation. 2000;  101 2788-2794
• 24 Weaver W D, Sirmes R J, Betriu A. et al . Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction.  JAMA. 1997;  278 2093-2098
• 25 Webb J G, Sleeper L A, Buller C E. et al . Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry.  J Am Coll Cardiol. 2000;  36 1084-1090 (Suppl A)
• 26 Werner G S, Diedrich J, Kreuzer K. Causes of Failed Angioplasty for Acute Myocardial Infarction Assessed by Intravascular Ultrasound.  Am Heart J. 1997;  133 517-525
• 27 Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, Branny M, St’asek J, Formanek P. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trialCPRAGUE-2.  Eur Heart J. 2003;  24 94-104
• 28 Zahn R, Schiele R, Schneider S. et al . Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis.  J Am Coll Cardiol. 2000;  36 2064-2071
• 29 Zahn R, Schiele R, Schneider S. et al . Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: Can we define subgroups of patients benefiting most from primary angioplasty.  J Am Coll Cardiol. 2001;  37 1827-1835